TP53 and ovarian carcinoma: Platinum analogue (the other component of standard regimen in ovarian cancer) effectiveness is modified by numerous factors such as epigenic changes in cancer cells, expression of multidrug resistance proteins (for example: P-gp, MRP1, MRP2, LRP), p53 gene mutations and GST-pi increase [19].